INO:NASDAQ

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.
INO:NASDAQ

Expert Comments:

Nick Hodge's Early Advantage (11/10/16)
"The Trump Bump has seen Inovio Pharmaceuticals Inc. rise nearly 28% in the past five days. It reported a $20.8 million Q3 loss this week, beating on revenues of $12.5 million. . .this play isn't about quarterly earnings. It's about the multiple drugs it has in development for serious diseases with major pharmaceutical partners. . .we're up 12% on Inovio and it remains a buy."

Ram Selvaraju, H.C. Wainwright & Co. (11/10/16)
"Inovio Pharmaceuticals Inc. total revenue was $12.5M, and net loss was $20.8M during the quarter, or ($0.28) per share. . .management expects to complete the FDA requirement regarding additional data on the shelf-life of the disposal part of the Cellectra® 5PSP delivery device in 1Q17. . .management has indicated that this pivotal study for VGX-3100 is scheduled to enroll approximately 400 subjects, up from 350 subjects as previously suggested. . .the company plans to have three drug candidates ready for registration in 2020. . .Inovio had $119.7M in cash and investments, which should fund operations into 2018."

Charles Duncan, Piper Jaffray & Co. (11/9/16)
"Inovio Pharmaceuticals Inc.'s lead program of ‘3100 in cervical dysplasia unfortunately remains on clinical hold. . .we believe the known concerns re: shelf-life of the CELLECTRA device can be efficiently addressed with 6-week non-clinical testing that Inovio has already initiated. . .while visibility is constrained in the near-term, following today's updates we remain buyers of INO shares in anticipation of a smooth turn-around and 1H17 trial start for ‘3100, and upside from its Phase I Zika (4Q16) and Ebola (1H17) results."

Zacks Equity Research (11/9/16)
"Inovio Pharmaceuticals Inc.'s VGX-3100 is the most advanced candidate in the company’s pipeline. It has completed a phase II study on VGX-3100 for the treatment of cervical dysplasia. Apart from VGX-3100, the company has several other candidates in its pipeline."

Jason Wittes, Aegis Capital (11/7/16)
"Inovio Pharmaceuticals Inc. is entering Phase III with its VGX-3100 for HPV-related precancers/cervical dysplasia (expected 1H17). This trial was recently put on hold due to a stability issue with updated disposable parts. . .the issue should be easily resolvable (the company anticipates a resolution by year end), but does delay the start of the trial by three to six months. . .the company has a large portfolio of cancer immunotherapy targets including head & neck and prostate (INO-5150 PSMA and PSA), both of which will read out Phase I data in Q4."

Nick Hodge's Early Advantage (11/3/16)
"Inovio Pharmaceuticals Inc. took a slide after the FDA placed a 'hold' on its proposed phase III program for VGX-3100. . .the program hadn't started nor had patients been recruited. And for assurance, the FDA has not cancelled the study, it has simply requested more information, which Inovio will supply. . .expect the phase III study to advance after this brief delay."

Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination.
read more >

More Expert Comments

Experts Following This Company

Larry Biegelsen – Wells Fargo Securities
Jim Birchenough – BMO Capital Markets
Yi Chen, Managing Director of Equity Research – Rodman & Renshaw
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Dorman Followwill, Partner and Director EIA – Frost & Sullivan Inc
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason Kolbert, Senior Analyst – Maxim Group
Chen Lin What Is Chen Buying? What Is Chen Selling?
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Inovio Pharmaceuticals Inc. Content